Impairment caused by Amyotrophic lateral sclerosis (ALS) is multidimensional (e.g. bulbar, fine motor, gross motor) and progressive. Its multidimensional nature precludes a single outcome to measure disease progression. Clinical trials of ALS use multiple longitudinal outcomes to assess the treatment effects on overall improvement. A terminal event such as death or dropout can stop the follow-up process. Moreover, the time to the terminal event may be dependent on the multivariate longitudinal measurements. In this article, we develop a joint model consisting of a multidimensional latent trait linear mixed model (MLTLMM) for the multiple longitudinal outcomes, and a proportional hazards model with piecewise constant baseline hazard for the event time data. Shared random effects are used to link together two models. The model inference is conducted using a Bayesian framework via Markov chain Monte Carlo simulation implemented in Stan language. Our proposed model is evaluated by simulation studies and is applied to the Ceftriaxone study, a motivating clinical trial assessing the effect of ceftriaxone on ALS patients.
Introduction
Amyotrophic lateral sclerosis (ALS), sometimes referred to as Lou Gehrig's Disease, is a neurodegenerative disorder characterised by progressive muscular paralysis reflecting degeneration of motor neurones in the primary motor cortex, corticospinal tracts, brainstem and spinal cord. 1 ALS is the most common motor neuron disease and the majority of ALS patients die of respiratory failure within two to five years of clinical onset. Typically, 30,000 Americans have the disease at any given time. People of all races and ethnic backgrounds are affected. The pathogenesis of ALS remains largely unknown and there is no cure, while many clinical trials are conducted to search for neuroprotective treatments capable of extending the length and meaningful quality of life for patients (e.g. the study of Ceftriaxone, 2 the PRO-ACT database, 3 and the study of MCI-186 4 ). ALS causes impairment in multiple domains (e.g. bulbar, motor, and respiratory). The disease progresses heterogeneously in time and across domains: decline may be observed in some, but not all health outcomes at any given time interval and the trajectory of progression may vary between different domains. Therefore, no single health outcome reliably reflects the full spectrum of ALS severity and progression.
Commonly used endpoints in ALS trials include assessments of muscle strength, respiratory function, and mortality. 5 However, these assessments require specialized equipment to administer and can be time-consuming. In contrast, the ALS Functional Rating Scale (ALSFRS) provides a physician-generated estimate of the patient's degree of functional impairment, evaluating multiple clinical aspects of ALS, including bulbar, fine motor, gross motor function, and respiratory disability. 6 The ALSFRS includes 10 questions (Web Table 1 ) rating patients' level of functional impairment in performing common tasks, e.g. Item 1 (speech) and Item 5 (cutting food). Each task is rated on a five-point scale from 0 (unable to attempt the task) to 4 (normal ability) at multiple visits during the ALS trials, leading to the multivariate longitudinal data structure. The summated ALSFRS total score (sum of the scores of all 10 ordinal ALSFRS items, with the range of 0-40) has been frequently used to evaluate patients' overall disease severity. [7] [8] [9] However, researchers are increasingly suggesting that the total score (derived by summing multiple ordinal items) is a relatively imprecise indicator of underlying disease severity because it ignores the differences among various response patterns that result in identical total score. 10, 11 To this end, Bacci et al. 5 applied Rasch 12 and Graded Response Model 13 under the item response theory (IRT) framework to each item of the ALSFRS, which provides information on the scaling metrics and item-level performance of an instrument, as well as specific characteristics of the scale. To account for the complex correlation structure in multivariate longitudinal data, an extension of the IRT framework, the multilevel IRT model has been developed. [14] [15] [16] A common feature of the multilevel IRT model is that a univariate latent variable representing the unobserved true disease severity is regressed on predictors (e.g. treatment and time) and subject-specific random effects (describing the between-subject differences), where the multiple items are viewed as clinical manifestations of the latent variable. This unidimensional assumption has been relaxed in Wang and Luo 17 by developing a multidimensional latent trait linear mixed model (MLTLMM) to allow multiple latent variables and withinitem multidimensionality (one outcome can be a manifestation of more than one latent variable) in the analysis of the multivariate longitudinal data.
During the follow-up process of ALS studies, some patients may have terminal events such as death, dropout, and withdrawal of consent. The terminal events and the multivariate longitudinal measurements are often not independent. For example, more severe ALS (as manifested by the ALSFRS) often increases the risk of death, which in turn makes any subsequent ALSFRS measurement impossible. The presence of such a dependent failure time is often termed as ''informative dropout,'' ignoring which could lead to biased estimates. 18 To address this issue, joint analysis of survival with repeated measures has been increasingly common. [19] [20] [21] [22] In this article, we develop a joint modeling framework in which a MLTLMM that allows multiple latent variables and within-item multidimensionality is used for multivariate longitudinal outcomes and a proportional hazards model with piecewise constant baseline hazard is used for the dependent terminal event. The two models are linked via shared random effects. The rest of the article proceeds as follows. In Section 2, we describe a motivating clinical trial. Section 3 discusses the joint MLTLMM model, Bayesian inference, and Bayesian model selection criteria. Section 4 provides a simulation study to assess the performance of the proposed model. In Section 5, we apply the proposed model to the motivating clinical trial dataset. Section 6 gives some concluding remarks and discussions.
A motivating clinical trial
The methodological development is motivated by the Ceftriaxone study, 2 a double-blind, placebo controlled multiphase clinical trial (completed in July 2012) with 513 subjects to determine if ceftriaxone slows the disease progression of ALS. The revised ALS Functional Rating Scale (ALSFRS-R) is the primary outcome in the Ceftriaxone study, which includes the 10 original ALSFRS items used in Wang and Luo 17 and two additional items. To obtain comparable results, the two additional items are excluded. In the Ceftriaxone study, ALSFRS was measured at 21 visits (screening, week 4, week 16, and every eight weeks starting from week 16 to week 152, plus a final study visit performed when subject completes trial), leading to multivariate longitudinal data structure (multiple ALSFRS items were repeatedly measured). Five subjects are excluded because of missing ALSFRS or the variable of forced vital capacity (FVC) at baseline and the analysis is based on the remaining 508 patients (172 in placebo and 336 in Ceftriaxone). In Wang and Luo, 17 we found three ALS impaired domains among the 10 items, i.e. bulbar function (including items of speech, salivation, and swallowing), fine motor function (including items of handwriting, cutting, and dressing), and gross motor function (including items of walking and climbing), while Item 7 (turning) overlaps on the fine motor and gross motor functions and Item 10 (breathing) slightly loads on the bulbar function.
Before the end of the study, some patients (86 and 164 patients in the placebo and Ceftriaxone groups, respectively) died. Time to death may be correlated with the ALSFRS because the more severe ALS, patients (with lower ALSFRS scores) have increased risk of death. To visualize the correlation between the terminal event and the outcome measurement, Figure 1 shows Item 2 (salivation) score over time for each patient who died with over 1.5 years of follow-up (first panel), who was censored with over 1.5 years of follow-up (second panel), who died with less than or equal to 1.5 years of follow-up (third panel), and who was censored with less than or equal to 1.5 years of follow-up (fourth panel). At any time point, patients with longer survival time tend to have higher salivation score (less severe ALS) compared with those with shorter survival time (first panel vs. third panel), suggesting that patients with longer survival times may have better health condition and slower disease progression. Similar patterns are observed in other items. To this end, we will develop a joint modeling framework with multidimensional latent trait model to account for the disease impairment in multiple domains and proportional hazards model for time to death.
Model and estimation 3.1 Model Formulation and Likelihood
In the context of clinical trials with multiple outcomes, the data structure is often of the type fy ik ðt ij Þ, t i , i g, where y ik ðt ij Þ is the kth (k ¼ 1, . . . , K) outcome, which can be binary, ordinal, or continuous, for subject i (i ¼ 1, . . . , I) at visit j (j ¼ 1, . . . , J i ) recorded at time t ij from the study onset, t i ¼ minðT Ã i , C i Þ is the observed event time to functional disability, as the minimum between the true event time T Ã i and the censoring time C i which are assumed to be independent, and d i is the censoring indicator (1 if the event is observed, and 0 otherwise). To illustrate the MLTLMM modeling framework, we assume that there are P (with P < K) latent variables (LVs) representing the underlying disease severity scores and denote them as h i ðtÞ ¼ ð 0 are the parameters specific to outcome k, the random errors " ik ðtÞ $ Nð0,
Þ are independent and identically distributed, and l ¼ 1, 2, . . . , n k À 1 is the lth level of the kth outcome, which is ordinal with n k categories. A major feature of these models is that they all incorporate h i ðtÞ and explicitly combine information from all outcomes. This is one of the simplest ways to conceptualize the disease severity scores that allow the overall treatment effects to be defined. To model the dependence of severity scores h i ðtÞ on covariates, we propose the second level multivariate linear mixed model (LMM) 
, which is the K by P latent factor loading matrix. Because the MLTLMM model is over-parameterized, additional constraints are required to make it identifiable, which has been discussed in detail in Wang and Luo. 17 Let the parameter vector be
ð pÞ e g. Conditional on the random effects u i , all the measurements of each subject are assumed to be independent. We have the full likelihood of multiple longitudinal outcomes for subject i as follows
where pðu i jAEÞ is the density function of random effects vector u i . To model the survival process, we use the proportional hazards model
where m measure the association between the two models linked together via the shared random effects u i . Although some covariates in the covariate vector W i may overlap with X i ðtÞ, W i does not include any timevarying covariates. We adopt a piecewise constant function to approximate the baseline hazard function h 0 ðtÞ. It has been shown that survival models using a piecewise constant baseline hazard function yield good estimators for both fixed effects and frailty, 23, 24 although fixed cut points need to be specified a priori. It is more flexible than assuming a particular parametric baseline hazard distribution (e.g. a Weibull distribution) and it retains enough model structure. 25 Specifically, given a set of fixed time points 1 , 2 , . . . , Q and 0 ¼ 0 or the smallest failure time and the baseline hazard vector g ¼ ðg 1 , g 2 , . . . , g Q Þ 0 , we define the piecewise constant baseline hazard function as h 0 ðtÞ ¼ P Q q¼1 g q I q ðtÞ, with indicator function I q ðtÞ ¼ 1 if qÀ1 t 5 q and 0 otherwise. The likelihood of observing event outcome t i and d i for subject i is
where the survival function S i ðt i Þ ¼ expfÀ R t i 0 h i ðsÞdsg and the parameter vector for the survival process is
Note that the shared random-effects formulation in the survival model (4) leads to a closed-form expression for the survival function S i ðt i Þ which provides a great computational advantage. In addition, we consider a special case of the model where the occurrence of the terminal event is independent to the longitudinal outcomes (i.e. m ¼ 0) and we refer to it as the reduced model (RM).
Bayesian inference and model selection
To make inference on the parameter vector Â, we use Bayesian methods based on Markov chain Monte Carlo (MCMC) posterior simulations. The prior distributions of parameters a k of the continuous outcomes is a k $ Nð0, 100Þ, with mean 0 and variance 100. To obtain the prior distributions for the threshold parameters of ordinal outcome k, we let a k1 $ Nð0, 100Þ, and
normal distribution left truncated at 0. Prior distributions for all elements in b (except for constrained parameters, see Wang and Luo 17 ), b, c and m are N(0, 100). We use the prior distribution Uniform ½À1, 1 for all the correlation coefficients q in the covariance matrix AE, and Inverse-Gamma ð0:01, 0:01Þ for all variance and covariance parameters. The model fitting is implemented in Stan (version 2.17.0), 26 which is a probabilistic programming language implementing statistical inference. Note that Stan requires variable types to be declared prior to modeling. The declaration of matrix AE as a covariance matrix ensures it to be positive-definite by rejecting the samples that cannot produce positive-definite matrix AE. Multiple chains with over-dispersed initial values are run to analyze data and the Gelman-Rubin diagnostic 27 is used to ensure that the scale reductionR of all parameters are smaller than 1.1. Moreover, we use the trace plots and autocorrelation functions to ensure the chain convergence. To facilitate easy reading and implementation of the proposed model, the Stan code is given in the Web Supplemental material.
There are a wide variety of model selection criteria in Bayesian inference. Because of the mixture framework in our model, we use the DIC 3 measurement. 28 The DIC 3 is defined as DIC 3 ¼ DðÂÞ þ D , where
io is a measure of the effective number of parameters in the model, and E ÂjD ð:Þ is the expectation with respect to the joint posterior distribution ðÂjDÞ, D denoting the observed data. Thus, 
Simulation studies
In this section, we conduct an extensive simulation study with two settings to investigate the performance of the proposed joint model (JM) and the simpler reduced model (RM). Specifically, we generate 200 datasets with sample size N ¼ 600 subjects and seven visits (baseline and six follow-up visits, J i ¼ 7) for each subject. The data structure is similar to the motivating Ceftriaxone dataset, and it has k ¼ 1, . . . , 10 ordinal outcomes with five categories each.
Specifically, we generate data by the following model In Setting I, we simulate data from the joint model by assuming Table 1 displays the bias (the average of the posterior means minus the true values), standard error (SE, the square root of the average of the posterior variance), standard deviation (SD, the standard deviation of the posterior means), and coverage probabilities (CP) of 95% equal-tail credible intervals from both the JM (true model) and RM. The results suggest that the joint model provides parameter estimates with very small biases, SE being close to SD, and the coverage probabilities being close to the nominal level of 0.95. In contrast, when all components in m are nonzero as in Setting I, incorrectly constraining all these parameters to 0 in the reduced model leads to inaccurate estimation results in the regression parameters of the latent process (i.e. b) and the parameters in the covariance matrix. For example, the reduced model gives biased estimates and poor CP for the regression parameters 
2 , as well as the variance/covariance parameters 2 , 4 , and q. Moreover, model selection criterion DIC 3 from JM is substantially lower than that from RM in all simulated datasets.
Geskus 30 indicates that in the random effects selection model (the survival process depends on the longitudinal process via random effects, similar to the JM in the current context), the parameters from the longitudinal subprocess can be estimated with little or no bias using only the longitudinal model if either (1) the occurrence of the terminal event only depends on observed longitudinal measurements, or (2) there are many measurements per individual, such that they contain sufficient information to estimate the trajectory with little bias. Neither of the two conditions is met in our simulation study. First, the occurrence of the terminal event is correlated with the longitudinal process via the shared random effects, which may also depend on unobserved longitudinal measurements. Second, the median number of measurements per individual in the simulation datasets is 5 (range is 1 À 7), which may not contain sufficient information of the trajectory, as compared with 14 CD4 measurements (range is 1 À 59) or 8 RNA measurements (range is 1 À 55) in the examples from Geskus.
30
Thus, the reduced model without considering the association process provides inaccurate estimation.
As pointed out by a reviewer, because the simulated censoring time is independent of the survival process, there should be no bias in the estimate of the regression parameter c in model (4) when treatment is the only covariate. The large difference in the estimates of c and the baseline hazard h 0 between two models is due to model non-collapsibility, where random effects are left out from the RM model. The estimates of the outcome-specific parameters a and b are presented in Web Tables 2 and 3 . Results from Setting I suggest that when the association between the survival process and the latent variable process is ignored, the estimates for b and variance/covariance matrix are biased. However, the ignorance of process association does not impact on the estimation of latent variables as well as a and b. A similar observation (reduced models have reasonable estimates of a and b) has also been made in our prior works. In Setting II, we simulate data from the reduced model by assuming
16,31
2 ¼ 0 so that the hazard of the terminal event does not depend on any of the latent variables, while all other parameters remain the same. The results in Table 2 and Web Tables 4 and 5 suggest that both models generate comparable results, i.e. the bias is negligible, SE is close to SD, and the credible interval coverage probabilities are reasonably close to 95%. Model selection criterion DIC 3 from both models is comparable in all simulated datasets. Under model overparameterization, the estimates of elements in m from the joint model are correctly close to zero.
In conclusion, the simulation results suggest that when the time to the terminal event is dependent on the multivariate longitudinal outcomes, model RM gives inaccurate estimation results in the regression parameters of the latent process and the parameters in the covariance matrix. In contrast, when the terminal event and the multivariate longitudinal outcomes are independent, both the models JM and RM give comparable results.
Application to the Ceftriaxone Study
In this section, following Wang and Luo, 17 we apply the proposed joint MLTLMM model and the Bayesian inference framework to the motivating Ceftriaxone study. In Wang and Luo, 17 we detected three dimensions in the 10 items of ALSFRS. Specifically, we compare the joint model and the reduced model with either 3 or 1 latent variables (denoted as JM 3LV , RM 3LV , JM 1LV and RM 1LV , respectively). We consider the following covariates for all latent variables: the treatment assignment variable trt i (1 for active, and 0 for placebo), time in year t ij , time and treatment interaction, and forced vital capacity (FVC) at baseline fvc i . In addition, we consider the treatment assignment and FVC in the proportional hazards model. Hence, we fit the following model: Using a 4-Core 3.6 GHz Intel E3-1271 processor, the total runtime is 9 h. Table 3 compares models JM 3LV , RM 3LV , JM 1LV , and RM 1LV using Bayesian model selection criteria. Model JM 3LV performs significantly better than the other three models with smaller " D, DIC 3 , EAIC and EBIC. Moreover, both joint models JM 3LV and JM 1LV outperform their reduced model counterparts RM 3LV and RM 1LV , respectively, suggesting that joint modeling is essential and it improves the model fitting. Web Figure 1 displays the Cox-Snell residual plot from JM 3LV , indicating an overall good model fit. Thus, we select model JM 3LV as the final model. Table 4 presents the factor loading matrix for model JM 3LV . Results in Table 4 are similar and consistent with Table 3 in Wang and Luo, 17 i.e. the three latent variables ð1Þ , ð2Þ , and ð3Þ are the underlying disease severity associated with bulbar, fine motor, and gross motor functions, respectively. Table 5 and Web Tables 6, 7 and 8 
Discussion
Clinical studies of many complex diseases often witness that the longitudinal outcomes are subject to dependent terminal events. Ignoring such dependence leads to biased estimates. In this article, we have proposed a joint modeling framework consisting of a multivariate latent trait linear mixed model and a proportional hazards model to jointly analyze the multivariate longitudinal data subject to dependent terminal events. Two models are linked together via shared random effects representing the subject-specific disease severity. The proposed joint model has a better fit than the reduced model in the analysis of the Ceftriaxone study. We have found that ALS patients with worse baseline bulbar and gross motor functions and with faster progression rates in these functions tend to have higher death hazard. The simulation studies have shown that in the presence of a dependent terminal event, the joint model successfully recovers the true parameters whereas the reduced model gives biased estimates for the regression parameters and the variance/covariance parameters. Under the scenario of independent terminal event, the joint model provides results comparable with the true reduced model.
There are some limitations in our proposed model that we will address in the near future. First, the multivariate longitudinal outcomes and time to death are linked by shared random effects in this study. This time-independent formulation leads to a closed-form solution for the integral in the survival model and renders great computational advantage. Other functional forms of joint models that allow a reasonable summary of the whole longitudinal trajectories have been proposed. 32 To this end, Rizopoulos et al. 33 investigated various association structures between the longitudinal and event time responses and used Bayesian model averaging (BMA) to combine various joint models with different association structures. However, functional forms in the context of multiple latent variables deserve more research effort. Second, our model for ordinal outcomes requires the proportional odds assumption. Statistical tests to evaluate this assumption in the traditional ordinal logistic regression have been criticized for having a tendency to reject the null hypothesis (that the sets of coefficients are the same between each pair of outcome groups), in cases where the assumption does hold. 34 Tests of the proportional odds assumption in the longitudinal latent variable setting are not well established, and the consequence of violating the assumption is unclear and worth future examination. In addition, we have chosen a multivariate normal distribution for the random effects vector because it is flexible in modeling the covariance structure within and between various types of longitudinal outcomes and it has meaningful interpretation on correlation. In generalized linear mixed models, misspecification of random effects distribution has little impact on the parameters that are not associated with the random effects. [35] [36] [37] The impact of random effects misspecification in the proposed modeling framework warrants further investigation. We will also investigate the effect of random effects misspecification and relax the normality assumption by considering Bayesian non-parametric (BNP) framework based on Dirichlet process mixture. 38 
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